Xvivo Perfusion AB (publ)

LSE:0RKL Stock Report

Market Cap: SEK 14.9b

Xvivo Perfusion Past Earnings Performance

Past criteria checks 4/6

Xvivo Perfusion has been growing earnings at an average annual rate of 68.4%, while the Medical Equipment industry saw earnings growing at 1.9% annually. Revenues have been growing at an average rate of 30.8% per year. Xvivo Perfusion's return on equity is 9.8%, and it has net margins of 27.2%.

Key information

68.4%

Earnings growth rate

66.8%

EPS growth rate

Medical Equipment Industry Growth-9.5%
Revenue growth rate30.8%
Return on equity9.8%
Net Margin27.2%
Next Earnings Update28 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Xvivo Perfusion makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0RKL Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24751204358144
30 Jun 24699121342140
31 Mar 24643100328140
31 Dec 2359892309136
30 Sep 2357324296109
30 Jun 235242727498
31 Mar 234632824779
31 Dec 224151822369
30 Sep 223703021161
30 Jun 223282318655
31 Mar 22293717158
31 Dec 21258815354
30 Sep 21233-2413565
30 Jun 21221-3713766
31 Mar 21192-4411663
31 Dec 20180-4410867
30 Sep 20182-269558
30 Jun 20194-67964
31 Mar 20220128765
31 Dec 1922159363
30 Sep 19217128657
30 Jun 1920378652
31 Mar 1919397951
31 Dec 18188137048
30 Sep 18171136845
30 Jun 18162136743
31 Mar 18153106241
31 Dec 1714866439
30 Sep 1714506040
30 Jun 1714506341
31 Mar 1714206139
31 Dec 1613825637
30 Sep 1613255634
30 Jun 1612774632
31 Mar 1612264632
31 Dec 1512054531
30 Sep 1511344233
30 Jun 1510944031
31 Mar 159833726
31 Dec 148553423
30 Sep 147963318
30 Jun 147473217
31 Mar 147173016
31 Dec 136982915

Quality Earnings: 0RKL has a high level of non-cash earnings.

Growing Profit Margin: 0RKL's current net profit margins (27.2%) are higher than last year (4.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0RKL's earnings have grown significantly by 68.4% per year over the past 5 years.

Accelerating Growth: 0RKL's earnings growth over the past year (748.3%) exceeds its 5-year average (68.4% per year).

Earnings vs Industry: 0RKL earnings growth over the past year (748.3%) exceeded the Medical Equipment industry 39.9%.


Return on Equity

High ROE: 0RKL's Return on Equity (9.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 01:28
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xvivo Perfusion AB (publ) is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dylan van HaaftenBryan Garnier & Co
Maria Vara FernándezBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB